Risk of inflammatory bowel disease in patients with rosacea: Results from a nationwide cohort study in Taiwan - 18/04/17
Abstract |
Background |
A link between rosacea and inflammatory bowel disease (IBD) has been proposed with unknown mechanisms. Epidemiologic evidence of this association needs to be examined.
Methods |
In this nationwide cohort study, a total of 89,356 patients with rosacea and 178,712 matched patients without rosacea between 1997 and 2013 were identified in the Taiwanese National Health Insurance Research Database. Cumulative incidences of IBD were compared between these 2 cohorts. Frailty Cox proportional hazard model was used and subgroup analyses were conducted to examine the risk factors for IBD.
Results |
The 15-year cumulative incidences of IBD were 0.036% (95% confidence interval [CI] 0.00%-1.57%) and 0.019% (95% CI 0.00%-0.83%) in rosacea and nonrosacea cohorts, respectively (P = .05). Rosacea (adjusted hazard ratio 1.94, 95% CI 1.04-3.63, P = .04) and male gender (adjusted hazard ratio 3.52, 95% CI 2.03-6.11, P < .01) were independently associated with IBD, after adjustment for major comorbidities. Multivariate subgroup analyses revealed consistent results. The incidence rates of IBD decreased with increasing antibiotic use in patients with rosacea, but without statistical significance.
Limitation |
Information related to lifestyle, diet, alcohol, and smoking was not included in the database.
Conclusion |
Patients with rosacea may have an increased risk of IBD.
Le texte complet de cet article est disponible en PDF.Key words : Crohn's disease, inflammatory bowel disease, nationwide cohort study, rosacea, ulcerative colitis
Abbreviations used : IBD, ICD-9-CM, NHIRD
Plan
Drs Wu and Chang contributed equally as first authors. |
|
Supported by grants NSC 102-2628-B-010-013 MY2 (National Science Council, Taiwan), TCVGH-1036802C, TCVGH-1036803C (Taichung Veterans General Hospital), and FJCU-A0203111 (Fu Jen Catholic University). |
|
Conflicts of interest: None declared. |
Vol 76 - N° 5
P. 911-917 - mai 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?